



PRESS RELEASE

U.S. patent granted for BUPI

STOCKHOLM, May 2nd, 2018, Moberg Pharma AB (OMX: MOB) announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently in development for pain due to oral mucositis. This patent should provide protection through to 2032.

The U.S. patent covers a method for the treatment of pain due to oral mucositis in cancer patients by locally administering a sustained-release lozenge in which the local anesthetic bupivacaine is the active ingredient. This patent should provide protection through to 2032. Moberg Pharma has previously announced patent grants in Europe and Canada.

"This issuance of this patent in the United States is part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products and is an important milestone, as we now have granted patents in all territories where we have applied for patent protection." commented Peter Wolpert, Moberg Pharma's CEO.

In 2016, Moberg Pharma announced positive Phase 2 results with BUPI in treating pain associated with oral mucositis in patients with head and neck cancer undergoing radiotherapy. Moberg Pharma estimates that the product has a sales potential amounting to USD 100–200 million annually, assuming successful commercialization in oral mucositis and at least one further indication.

For additional information, please contact:

Peter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on May 2nd, 2018.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ.) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], New Skin[®], Dermoplast[®] and Domeboro[®]. Kerasal Nail[®] (Emtrix[®], Zanamira[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis, phase 3 studies ongoing) and BUPI (pain management in oral mucositis, preparations for phase 3 studies ongoing). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).